EP1686965A2 - Solid pharmaceutical preparation form - Google Patents

Abstract

The invention relates to a solid pharmaceutical preparation form containing one or more solid excipients and/or adjuvants and an active substance from the group consisting of monoamine neurotransmitter reuptake inhibitors that have a 2,3-disubstituted tropane skeleton. The invention also relates the production of this preparation form and to the use thereof for producing a medicament for treating or preventing central nervous system diseases or disorders.

Description

 SOLID PHARMACEUTICAL PREPARATION FORM

BACKGROUND OF THE INVENTION 1. TECHNICAL FIELD

The invention relates to a solid pharmaceutical preparation containing one or more solid carriers and / or excipients and an active ingredient from the group of monoamine neurotransmitter re-uptake inhibitors with a 2,3-disubstituted tropane skeleton, their preparation and use for the manufacture of a medicament for Treatment or prevention of central nervous disorders or disorders.

2. State of the art

Monoamine Neurotransmitters Re-uptake inhibitors which have a 2,3-disubstituted tropane skeleton are compounds with pharmacologically valuable properties. They may, for example, have a high therapeutic benefit in the treatment of central nervous disorders such as dementia associated with Alzheimer's disease or Parkinson's disease.

Such compounds are known e.g. from International Patent Applications WO 93/09814 and WO 97/30997, in which various dosage forms for such compounds are also proposed.

Due to the very high potency of these compounds, there is a need for dosage forms with high stability and a low content of active ingredient. Such dosage forms make high demands on the manufacturing process in terms of content uniformity due to the low active ingredient loading. The required high unit uniformity is difficult to achieve with conventional manufacturing processes such as direct tableting or wet granulation.

The present invention was therefore based on the object of a solid pharmaceutical dosage form for monoamine neurotransmitter re-uptake inhibitors, which is a 2,3- Disubstituted tropane skeleton, with high stability, faster in vitro dissolution and good bioavailability and high content uniformity to provide.

It has now surprisingly been found that the disadvantages of conventionally prepared dosage forms, in particular with regard to the content uniformity can be overcome if one has a solution of an active ingredient from the group of Monoamm neurotransmitter re-uptalce inhibitors, which have a 2,3-disubstituted tropane scaffold on spraying a carrier and / or the dosage form or the spray medium contains a moist binder.

BRIEF SUMMARY OF THE INVENTION

The invention thus relates to a solid pharmaceutical preparation containing one or more solid carriers and / or excipients and an active ingredient from the group of monoamine neurotransmitter re-uptake inhibitors with a 2,3-disubstituted tropane skeleton which (a) by spraying a Solution of the active ingredient is available on at least one carrier; and (b) optionally one or more wet binders, preferably in the spray solution.

Another object of the invention is a process for the preparation of such pharmaceutical formulations, wherein

(A) an active ingredient selected from the group of monoammic neurotransmitter re-uptake inhibitors, which has a 2,3-disubstituted tropane skeleton, in a suitable solvent, optionally in the presence of an adjuvant dissolves;

(b) spraying the resulting solution onto one or more solid carriers;

(c) optionally adding further excipients and auxiliaries;

(d) shaping and optionally pressing the resulting mixture; and (e) optionally applying a suitable film coating.

Finally, the invention relates to the use of a pharmaceutical preparation according to any one of claims 1 to for the manufacture of a medicament for the treatment or prevention of central nervous disorders or disorders selected from the group consisting of depression, any form of dementia, Parkinson's disease or obesity.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the dissolution behavior of a pharmaceutical preparation according to the invention in the form of a film tablet with and without wet binding agent containing 1 mg of a compound of the formula LA at a pH of 1.2.

FIG. 2 shows the dissolution behavior of a pharmaceutical preparation according to the invention in the form of a film tablet with and without wet binding agent containing 1 mg of a compound of the formula IA at a pH of 6.8.

DETAILED DESCRIPTION OF THE INVENTION

As a rule, the monoamine neurotransmitter re-uptake inhibitors having a 2,3-disubstituted tropane skeleton are those of the formula (I) as disclosed, for example, in International Patent Applications WO 93/09814 and WO 97/30997:

or their pharmaceutically acceptable acid addition salts or their N-oxides, wherein

R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl;

R ^{3 is} CH ₂ -XR ', wherein X is O, S, or NR ", wherein R" is hydrogen or alkyl; and R 'is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or -CO-alkyl; Heteroaryl which may be monosubstituted or polysubstituted by alkyl, cycloalkyl or cycloalkylalkyl; Phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; phenylphenyl; Pyridyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; Thienyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or benzyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or (CH 2 CO ₂ R ¹¹ , COR ¹¹ , or CH ₂ R ¹² , wherein R ^{11 is} alkyl, cycloalkyl, or cycloalkylalkyl; phenyl which is mono- or polysubstituted by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, Alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; phenylphenyl; pyridyl which is mono- or polysubstituted by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro , and heteroaryl may be substituted, or thienyl which is one or more times may be substituted by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or benzyl; nist O or l; and R ¹² is O -phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or O-CO-phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or CH = NOR; wherein R 'is hydrogen; Alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl or aryl; which in turn is replaced by -COOH; -COO-alkyl; -COO-cycloalkyl may be substituted; or phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, and nitro; R ⁴ is phenyl, 3,4-methylenedioxyphenyl, benzyl, naphthyl, or heteroaryl which is mono- or polysubstituted by a substituent selected from the group consisting of halogen, CF, CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and Heteroaryl can be substituted.

Preference is given to compounds of the formula I in which

R ^{3 is} 1, 2,4-oxadiazol-3-yl, which may be substituted in the 5-position by alkyl, cycloalkyl, or cycloalkylalkyl; Phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; phenylphenyl; or Benzyl which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or R ^{3 is} 1, 2,4-oxadiazol-5-yl, which may be substituted in the 3-position by alkyl, cycloalkyl, or cycloalkylalkyl; Phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; phenylphenyl; or benzyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or

In a further preferred embodiment of the compounds of the general

Formula I is R ³ .CH ₂ -XR wherein

X is O, S, or NR "; wherein R" is hydrogen or alkyl; and

R 'is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, or -CO-alkyl.

Further preferred are the compounds of formula (I) wherein R ³ is CH = NOR '; in which

R 'is hydrogen; Alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl or aryl; which may be substituted by a substituent selected from the group consisting of -COOH; -COO-alkyl; -COO-cycloalkyl and phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, and nitro.

Preference is furthermore given to the compounds of the formula (I) in which R ⁴ is phenyl which is mono- or disubstituted by a substituent selected from the group consisting of halogen, CF, CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and Heteroaryl can be substituted. Particular preference is given to the compounds of the formula (I) in which R ^{4 is} phenyl which is monosubstituted or disubstituted by chlorine.

Also preferred are such 2,3-disubstituted tropane derivatives having a monoamine neurotransmitter re-uptake inhibitory activity which have a (1R, 2R, 3S) configuration.

Particular preference is given to the compounds of the formula (I) in which R ³

-CH ₂ -XR ', where X is O or S, and R' is methyl, ethyl, propyl, or

Cyclopropylmethyl;

-CH = NOR '; wherein R 'is hydrogen or alkyl; or 1, 2,4-oxadiazol-5-yl, which may be substituted in the 3-position by alkyl.

Furthermore, R is preferably hydrogen, methyl, ethyl or propyl.

Preference is given to the compounds of the formula I in which R ^{4 is} 3,4-dichlorophenyl.

Further preferred are the compounds of formula II,

wherein

R ^{1 represents} a hydrogen atom or a C _1-6 alkyl group, in particular hydrogen, methyl or ethyl;

R ^{2 is} a halogen atom or a is a CF ₃ or cyano group, especially fluorine, chlorine or bromine;

R ^{3 is} a hydrogen atom or a C _1-6 alkyl group or C _3-6 cycloalkyl C _1-3 alkyl group, especially methyl, ethyl or propyl; and m is 0 or an integer from 1 to 3, especially 1 or 2; or a tautomer, a pharmaceutically acceptable salt, solvate, or a physiologically functional derivative thereof.

The term "Cι_ ₆ alkyl" as used above and below includes methyl and ethyl groups, as well as geradketttige and branched propyl, butyl, pentyl and hexyl groups. Particularly preferred alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.

The term "C _3-6 cycloalkyl" as used above and below includes cyclic propyl, butyl, pentyl and hexyl groups such as cyclopropyl and cyclohexyl.

The term "halogen" as used above and below includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are particularly preferred.

The term "physiologically functional derivative" as used above and below includes derivatives obtained from the compounds of formula (I) under physiological conditions, such as N-oxides.

The term "pharmaceutically acceptable acid addition salts" as used hereinbefore and hereinafter includes acid addition salts formed with hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid and maleic acid, the salts of hydrochloric acid , Bromic acid, sulfuric acid, phosphoric acid, acetic acid and citric acid are particularly preferred. Most preferred is the salt of citric acid.

In a particularly preferred embodiment, the compounds of the formula (I) are selected from the group consisting of:

(1 R, 2 R, 3 S) -2- (3-cyclopropyl-1,2,4-oxadiazol-5-yl) -3- (4-fluorophenyl) tropane;

(1R, 2R, 3S) -2- (3-phenyl-1, 2,4-oxadiazol-5-yl) -3- (4-fluorophenyl) tropane;

(1R, 2R, 3S) -2- (3-phenyl-1, 2,4-oxadiazol-5-yl) -3- (4-methyl-phenyl) -tropane; (1 R, 2 R, 3 S) -2- (3-benzyl-1,2,4-oxadiazol-5-yl) -3- (4-fluorophenyl) tropane;

(1 R, 2 R, 3 S) -2- (3- (4-phenylphenyl) -1,2,4-oxadiazol-5-yl) -3- (4-fluoro-phenyl) -tropane;

(1R, 2R, 3S) -2- (3-phenyl-1,2,4-oxadiazol-5-yl) -3- (2-naphthyl) tropane;

(1R, 2R, 3S) -3- (3, 4-dichlorophenyl) troρane-2-aldoxime;

(1R, 2R, 3S) -3- (3, 4-dichlorophenyl) -tropan-2-O-methyl-aldoxime;

(1R, 2R, 3S) -3- (3,4-dichlorophenyl) tropane-2-O-benzyl-aldoxime;

(1R, 2R, 3S) -3- (3, 4-dichlorophenyl) tropane-2-O-ethoxycarbonylmethyl aldoxime;

(1R, 2R, 3S) -3- (3, 4-dichlorophenyl) tropane-2-O-methoxycarbonylmethyl-aldoxime;

(1R, 2R, 3S) -3- (3,4-dichlorophenyl) tropane-2-O- (1-ethoxycarbonyl-1,1-dimethyl-methyl) aldoxime;

(1R, 2R, 3S) -3- (3, 4-dichlorophenyl) tropane-2-O-carboxymethyl-2-aldoxime;

(1R, 2R, 3S) -N-normethyl-3- (3, 4-dichlorophenyl) tropane-2-O-methyl-aldoxime;

(1R, 2R, 3S) -N-normethyl-3- (3,4-dichlorophenyl) tropane-2-O-benzyl-aldoxime;

(1R, 2R, 3S) -3- (4-methylphenyl) tropane-2-O-methyl-aldoxime;

(1R, 2R, 3S) -3- (3,4-dichlorophenyl) tropane-2-O- (1,1-dimethylethyl) -aldoxime;

(1R, 2R, 3S) -3- (4-chlorophenyl) tropane-2-O-aldoxime;

(1R, 2R, 3S) -3- (4-chlorophenyl) tropane-2-O-methylaldoxime hydrochloride;

(1R, 2R, 3S) -3- (4-chlorophenyl) tropane-2-O-methoxycarbonylmethyl-aldoxime;

(1R, 2R, 3S) -3- (3, 4-dichlorophenyl) tropane-2-O- (2-propynyl) -aldoxime;

(1R, 2R, 3S) -3- (3,4-dichlorophenyl) tropane-2-O- (2-methylpropyl) -aldoxime;

(1R, 2R, 3S) -3- (3,4-dichlorophenyl) tropane-2-O-cyclopropylmethyl-aldoxime;

(1R, 2R, 3S) -3- (3, 4-dichloro-phenyl) -tropan-2-O-ethyl-aldoxime;

(1R, 2R, 3S) -2-methoxymethyl-3- (3, 4-dichlorophenyl) -tropane;

(LR, 2R, 3S) -2-isopropoxymethyl-3- (3,4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2-ethoxymethyl-3- (3, 4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2-ethoxymethyl-3- (3, 4-dichlorophenyl) -nortropane;

(1R, 2R, 3S) -2-cyclopropylmethyloxymethyl-3- (3, 4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2-methoxymethyl-3- (4-chlorophenyl) -tropane;

(1R, 2R, 3S) -N-normethyl-2-methoxymethyl-3- (4-chlorophenyl) -tropane;

(LR, 2R, 3S) -2-ethoxymethyl-3- (4-chlorophenyl) -tropane;

(1R, 2R, 3S) -N-normethyl-2-methoxymethyl-3- (3, 4-dichlorophenyl) -tropane; (LR, 2R, 3S) -N-normethyl-2-ethoxymethyl-3- (3,4-dichloroρhenyl) -tropane;

(1R, 2R, 3S) -N-normethyl-2-ethoxymethyl-3- (4-chlorophenyl) -tropane;

(1R, 2R, 3S) -N-normethyl-2-cyclopropylmethyl-oxymethyl-3- (4-chlorophenyl) -tropane;

(1R, 2R, 3S) -2-cyclopropylmethyloxymethyl-3- (4-chlorophenyl) -tropane;

(1R, 2R, 3S) -2-ethylthiomethyl-3- (3,4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2-hydroxymethyl-3- (4-fluorophenyl) tropane;

(1R, 2R, 3S) -2-hydroxymethyl-3- (3,4-dichlorophenyl) tropane;

(1R, 2R, 3S) -N-normethyl-N- (tert-butoxycarbonyl) -2-hydroxymethyl-3- (3,4-dichlorophenyl) tropane;

(1R, 2R, 3S) -2-hydroxymethyl_-3- (4-chlorophenyl) tropane;

(1R, 2R, 3S) -2- (3- (2-furanyl) -1,2,4-oxadiazol-5-yl) -3- (3, 4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2- (3- (3-pyridyl) -1,2,4-oxadiazol-5-yl) -3- (3, 4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -N-normethyl-N-allyl-2- (3- (4-pyridyl) -l, 2,4-oxadiazol-5-yl) -3- (3, 4-dichlorophenyl) - tropane;

(1R, 2R, 3S) -N-normethyl-N-ethyl-2- (3- (4-pyridyl) -l, 2,4-oxadiazol-5-yl) -3- (3,4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -N-normethyl-N- (2-hydroxyethyl) -2- (3- (4-pyridyl) -1,2,4-oxadiazol-5-yl) -

3- (3,4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -N-normethyl-2- (3- (4-pyridyl) -1,2,4-oxadiazol-5-yl) -3- (3, 4-dichlorophenyl) -tropan;

(1R, 2R, 3S) -N-normethyl-N-allyl-2- (3- (3-pyridyl) -1,2,4-oxadiazol-5-yl) -3- (3,4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -N-normethyl-N-allyl-2- (3- (2-pyridyl) -1,2,4-oxadiazol-5-yl) -3- (3,4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2- (3- (2-thienyl) -1,2,4-oxadiazol-5-yl) -3- (4-chlorophenyl) -tropane;

(1R, 2R, 3S) -2- (3- (2-Thienyl) -1,2,4-oxadiazol-5-yl) -3- (3, 4-dichlorophenyl) -troρane;

(1R, 2R, 3S) -2- (3- (4-pyridyl) -1,4,4-oxadiazol-5-yl) -3- (3, 4-dichloro-phenyl) -tropane;

(1R, 2R, 3S) -2- (3- (2-pyridyl) -1,2,4-oxadiazol-5-yl) -3- (3, 4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2- (3- (4-pyridyl) -1,2,4-oxadiazol-5-yl) -3- (4-chlorophenyl) -tropane;

(1R, 2R, 3S) -2- (3- (3-pyridyl) -1,4,10-oxadiazol-5-yl) -3- (4-chlorophenyl) -troρan;

(1R, 2R, 3S) -2- (3-2-pyridyl) -1,2,4-oxadiazol-5-yl) -3- (4-chlorophenyl) -tropane; (1 R, 2 R, 3 S) -2- (3-phenyl-1,2,4-oxadiazol-5-yl) -3- (4-fluoro-phenyl) -troρane;

(1R, 2R, 3S) -2- (3-phenyl-1, 2,4-oxadiazol-5-yl) -3- (4-methyl-phenyl) -troρane;

(1R, 2R, 3S) -2- (3-Benzyl-1,2,4-oxadiazol-5-yl) -3- (4-fluoro-phenyl) -tropane;

(1R, 2R, 3S) -2- (3- (4-phenyl-phenyl) -1,2,4-oxadiazol-5-yl) -3- (4-fluorophenyl) -tropane;

(1R, 2R, 3S) -2- (3-phenyl-1,2,4-oxadiazol-5-yl) -3- (2-naphthyl) -troρan;

(1R, 2R, 3S) -2- (4-chlorophenoxy-methyl) -3- (4-fluorophenyl) -tropane;

(1R, 2R, 3S) -2- (4-chloro-4-fluoro-phenyl) -tropane;

(1R, 2R, 3S) -2- (4-chlorophenoxy-methyl) -3- (3,4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2- (4-chlorophenoxy-methyl) -3- (4-methylphenyl) -troρane;

(1R, 2R, 3S) -2- (4-benzoyloxy-methyl) -3- (4-fluorophenyl) -tropane;

(1R, 2R, 3S) -2-carbomethoxy-3- (2-naphthyl) -tropane;

(1R, 2R, 3S) -2-carbomethoxy-3- (3,4-dichlorophenyl) -tropane;

(1R, 2R, 3S) -2-carbomethoxy-3-benzyl-tropane;

(1R, 2R, 3S) -2-carbomethoxy-3- (4-chlorophenyl) -tropane;

(1R, 2R, 3S) -2-carbomethoxy-3- (4-methylphenyl) -tropane;

(1R, 2R, 3S) -2-carbomethoxy-3- (1-naphthyl) -tropane;

(1R, 2R, 3S) -2-carbomethoxy-3- (4-phenylphenyl) -tropane;

(1R, 2R, 3S) -2-carbomethoxy-3- (4-t-butyl-phenyl) -tropane;

(1R, 2R, 3S) -2- (4-fluoro-benzoyl) -3- (4-fluorophenyl) -tropane; or their pharmaceutically acceptable salts.

Most preferred is the compound of formula LA

or a pharmaceutically acceptable salt, especially the citrate thereof.

Preferably, the pharmaceutical preparation of the invention contains up to 5.00 wt.%, Preferably 0.01 to 3.00 wt .-%, in particular 0.10 to 1.50 wt .-%, usually preferably 0.10 to 0.80 wt .-% of an active ingredient from the group of monoamine neurotransmitter re-uptake inhibitors having a 2,3-disubstituted tropane skeleton, wherein the percentages refer to the particular salt used this active ingredient.

Further preferred is a pharmaceutical preparation form obtainable by spraying a solution of the active ingredient, wherein the solvent contains water, an alcohol and optionally a wet binder. The ratio of the solvents alcohol and water may be 100: 0 to 0: 100 (wt%), preferably 20:80 to 80:20 (wt%), more preferably 40:60 to 60:40 (wt%) ,

Preferred wet binders are Polyvmylpynolidion (povidone), copolymers of vinylpyrrolidone with other vinyl derivatives (copovidones), cellulose derivatives such as methylhydroxypropylcellulose, methylcellulose or hydroxypropylcellulose, in particular hydroxypropylcellulose (HPC).

In a further preferred embodiment, the active ingredient precipitates on the carrier material during spraying in a predominantly crystalline form.

In the context of the present invention, carbohydrates such as lactose or mannose, in particular finely divided lactose and lactose monohydrate, but also or sugar alcohols such as mannitol, sorbitol or xylitol, in particular mannitol as carrier materials, are of particular importance. These carriers have proven to be particularly advantageous in the formulation according to the invention. A preferred aspect of the present invention therefore relates to a preparation containing at least one compound of formula I which, in addition to the active substance, contains lactose, in particular finely divided lactose and lactose monohydrate as carrier.

According to the invention, the weight ratio between the components lactose contained in the tablet to the active ingredient in a range of about 200: 1 to about 20: 1. Preferably, the ratio of lactose to the active ingredient is within a range of about 150: 1 to about 50: 1. Preferably, the weight fraction of lactose based on the total mass of the tablet according to the invention is in a range of about 50-80% by weight, preferably between about 55-75% by weight.

Further preferred are pharmaceutical preparation forms, wherein the carrier materials are selected from the group consisting of carbohydrates and dry binders.

Above and below, the term "dry binder" stands for those auxiliaries which are suitable for binding other components together.The binders preferred according to the invention are selected from the group consisting of: powdered cellulose, microcrystalline cellulose, sorbitol, starch, polyvinylpyrrolidone (povidone), copolymers of Vinylpyrrolidone with other vinyl derivatives (copovidones), cellulose derivatives, in particular methylhydroxypropylcellulose, eg Methocel E 5 P, and mixtures of these compounds Preferably, as binders, powdered cellulose, especially microcrystalline cellulose and / or copovidone are included Most preferred is microcrystalline cellulose.

Because of this particularly preferred carrier combination of microcrystalline cellulose, anhydrous lactose and lactose monohydrate tablets with high mechanical stability and at the same time rapid drug release and thus good bioavailability are obtained.

If one of the abovementioned dry binders is added to the formulation according to the invention, the weight ratio of lactose to binder is preferably about 5: 1 to about 1: 2, preferably about 3: 1 to about 1: 1, particularly preferably about 2.5: 1 to 1.5: 1.

Preference is furthermore given to pharmaceutical preparation foams, wherein the auxiliaries are selected from the group consisting of moist binders, lubricants, disintegrants, release agents and wetting agents. In the context of the present invention, these disintegrating agents may optionally also be referred to as disintegrating agents. According to the invention, these are preferably selected from the group consisting of sodium starch glycolate, cross-linked polyvinylpyrrolidones (crospovidone), croscarmellose sodium salt (cellulose carboxymethylether sodium salt, crosslinked), carboxymethylcellulose, dried corn starch and mixtures thereof. In the context of the present invention, particular preference is given to using sodium starch glycolate, crospovidone and, preferably, croscarmellose sodium salt. If the above-mentioned disintegrants are used, their weight fraction based on the total mass of the tablet according to the invention is preferably in a range of about 0.5-10% by weight, more preferably about 1.0-5.0% by weight.

Suitable lubricants for the purposes of the present invention include, for example, silica, talc, stearic acid, sodium stearyl fumarate, magnesium stearate and glycerol tribehenate. Vegetable magnesium stearate is preferably used according to the invention. If the flow or flow regulators or lubricants mentioned above are used, their weight fraction based on the total mass of the administration form according to the invention is preferably in a range of about 0.1-10% by weight, preferably about 0.5-5% by weight. more preferably between 0.6 and 1.0% by weight.

In a preferred embodiment, the preparation form according to the invention is a tablet, in particular a film-coated tablet.

In general, the film coating consists essentially of one or more film formers, one or more elasticity enhancing agents, the so-called plasticizers, one or more release agents, one or more pigments, and optionally one or more dyes.

Preferred is a film-coated tablet, wherein the film coating consists essentially of From 35 to 65% by weight of at least one film former, in particular HPMC; From 3.5 to 10% by weight of at least one elasticity-enhancing agent, in particular PEG; - 5 to 20 wt .-% of at least one coating, in particular a silicate; 10 to 40 wt .-% of at least one pigment, in particular titanium dioxide - 0 to 10% by weight of at least one dye, in particular of iron oxides. based on the total mass of the film coating.

Preference is given to a pharmaceutical preparation according to one of the preceding claims, characterized in that it consists essentially of the following components: (i) an active substance from the group of the monoamine neurotransmitter re-uptake inhibitors which have a 2,3-disubstituted tropane skeleton, preferably a compound of formula (I), in particular the compound of formula (IA); (ii) one or more carrier materials selected from the group consisting of carbohydrates and dry binders, preferably lactose and cellulose; (iii) one or more adjuvants selected from the group consisting of cellulose derivatives and salts of fatty acids, preferably HMC, CMC Na, cross-linked, and magnesium stearate; (iv) a film coating consisting essentially of one or more film formers, one or more elasticity enhancing agents, one or more release agents, one or more pigments, and optionally one or more colorants.

Particularly preferred is a pharmaceutical preparation in the form of a film tablet consisting essentially of the following components: (i) 0.01 to 5.00 wt .-% of an active ingredient from the group of monoamine neurotransmitter re-uptake inhibitors, which is a 2, 3-disubstituted Tropan skeleton, in particular 0.02 to 3.00 wt .-% of an active ingredient of the formula I; (Ii) 80.00 to 95.00 wt .-% of one or more carrier materials selected from the group consisting of carbohydrates and dry binders, in particular carrier materials consisting of: a. 27.5 to 32.5% by weight of anhydrous lactose; b. 27.5 to 32.5% by weight of lactose monohydrate; c. 25.0 to 30.0% by weight of microcrystalline cellulose; (Iii) l, 00 to 10.00 wt .-% of one or more adjuvants selected from the group consisting of cellulose derivatives and salts of fatty acids, in particular 2.00 to 8.00 wt .-% of one or more auxiliaries selected from the group consisting of HPC, CMC Na, cross-linked, and magnesium stearate; ; (iv) 0 to 10.00% by weight of a film coat consisting essentially of one or more film formers, one or more plasticizers, 1.00 to 5.00% by weight of a film coat comprising HPMC, MHPC, PEG, one or more silicates, titanium dioxide and one or more iron oxides or more pigments and optionally one or more dyes, especially 00 to 5.00 of a film coating comprising HPMC, MHPC, PEG, one or more silicates, titanium dioxide and one or more iron oxides.

To produce the preparation according to the invention, the active ingredient is dissolved in a solvent, optionally in the presence of a wet binder, sprayed onto the carriers, in particular finely divided, anhydrous lactose, lactose monohydrate and microcrystalline cellulose as binder, mixed, sieved and then dried. The product obtained is optionally cross-linked with further carrier, in particular microcrystalline cellulose and / or lactose, with disintegrants, in particular CMC Na, and finally with the flow agent, in particular magnesium stearate. The resulting mixture is then compressed on a suitable tablet press to give the tablets according to the invention. The pressing forces needed to produce tablets of suitable breaking strengths and thus the desired disintegration times depend on the shapes and sizes of the punching tools used. Preferably, pressing force is in a range of 2 - 30 kN, especially 5 - 26 kN. Higher press forces can lead to tablets with slower drug release. Lower press forces can lead to mechanically unstable tablets. The tablet cores can have different formats, preferred are round, large-domed or biconvex and oval or oblong forms.

Subsequently, a solution of the film-forming agent and the plasticizer is prepared in water, the insoluble release agents and pigments dispersed therein and the resulting suspension applied to the tablets.

The following examples serve to illustrate formulations according to the invention. They are to be understood merely as possible, exemplarily illustrated procedures, without restricting the invention to their content.

example 1

Film tablets are produced consisting of:

I. COMPOSITION

ingredients

(01) Formula (IA) citrate

(02) lactose fine

(03) Lactose monohydrate (

(04) Cellulose Microcryst. Type 101 (05) Hydroxypropyl Cellulose (Klucel EF Pharm)

(06) carboxymethylcell NA (Ac-Di-Sol)

(07) Magnesium Stearate Vegetable

(08) Hypromellose (Methocel E5 Premium)

(09) Macrogol 6000

(10) titanium dioxide

(11) Talc

(12) iron oxide yellow 17015

(13) iron oxide red 17009

(14) Ethanol 96%

(15) water cleaned

II. PRODUCT DESCRIPTION

III. MANUFACTURING

A) Tablets 1 batch final mix and tablets: 15000 g corresponds to 62500 tablets

1. Granulation Wash water in a suitable batch kettle (15) and add 1120,000 g (14) ethanol 96% PAR INT 1680,000 g (room temperature). Add successively (05) hydroxypropylcellulose (Klucel EF Pharm) INT 150,000 g and (01) formula (IA) citrate 99,063 g and dissolve. Solids content: 249.063 g 3049.063 g

Process data: Stirrer: SPN stirrer Speed / duration: approx. 250 - 450 rpm

2. Granules In a suitable one-pot granulator (02) Lactose fine INT 4963.437 g (03) Lactose monohydrate (Tablettose) TNT 4875,000 g and

(04) Cellulose microcryst. Mix type 101 INT 4500.000 g Homogenous and mix with the granulating liquid 1. Dampen 3049.063 g of solids: 249.063 g, granulate and then dry. 14587,500 g

Process data: Intensive mixer: Zanchetta Roto P 50

Nozzle head: 1.1 mm Spray pressure: approx. 2 bar Swivel angle: 100 ° (for drying and cooling)

During drying and cooling, the mixer should run on interval switching, i. Mix for 1 minute, then 2 minutes rest.

3. Dry sieve Use a suitable sieving machine to grind the dried granules.

Process data: Screening machine: Comil 197 S Screen size: RS 2007 Spacer ring: DR 125 4. Final Mix In a suitable tumbler mixer, mix dry sieve 3. 14587.500 g with (07) carboxymethylcell-NA, cross-linked (Ac-Di-Sol) INT 300,000 g. Then add (06) magnesium stearate plant INT 112.500 g pre-screened over 0.5 mm and mix homogeneously.

15,000,000 g

Process data: Free-fall mixer: Servolift Kubus 60 1 Mixing speed: 10 rpm Number of revolutions: 100 U (Ac-Di-Sol INT) 30 U (MgSt.INT)

Tablets On a suitable tablet press the final mixture 4. Press 15000,000 g into tablets. Target weight: 240 mg

Process data: Tablet press: Korsch EK0 Tool: 9 mm WR 13.5, big arched with facet + BI logo Press speed level 4 Pressing force: approx. 11-12 kN

B) film-coated tablets

1 batch 2640 g = 11000 tablets 2695 g = 11000 film-coated tablets

6. Coating suspension / solution (15) Water purified 261.800 g (08) Hypromellose (Methocel E5 Prem) INT 27.500 g (07) Macrogol 6000 INT 2,750 g Place in a suitable container (15) at room temperature (08) and (07) Stir and dissolve (at least 15 minutes). Solids content 30.250 g 292.050 g

7. Coating suspension / dispersion (15) Purified water 112.200 g (10) Titanium dioxide INT 13.750 g (11) Talc INT 8.250 g (12) Iron oxide yellow 17015 INT 1.375 g (13) red iron oxide 17009 INT 1.375 g In a suitable container (15 ) at room temperature (10), (11), (12) and (13) using an Ultra-Tunax and stir for 30 minutes. Solids content 24.750 g 136.950 g 8. Coating suspension Coating suspension / solution 6. 292.050 g coating suspension / dispersion 7. 136.950 g Stir the dispersion into solution 6., and then stir for 5 minutes. Solids 55,000 g 429,000 g

Feeding In a suitable film coating machine Tablet cores 5. 2640,000 g coating suspension 8. 429,000 g Cover to a weight of 245 mg. Solids 55,000 g 2695,000 g

Example 2

Analogously to Example 1, corresponding non-coated tablets are prepared, wherein a solution of the active ingredient of the formula (IA) in the form of the citrate dissolved in water and ethanol but without the addition of hydroxypropyl cellulose is applied to the carrier material.

Example 3

I. COMPOSITION

ingredients

(01) Foπnel (IA) citrate

(02) lactose fine

(03) Lactose monohydrate (

(04) Hydroxypropylcellulose (Klucel EF Pharm)

(05) Cellulose Microcryst. Type 101

(06) carboxymethylcell NA (Ac-Di-Sol)

(07) Magnesium Stearate Vegetable

(08) Hypromellose (Methocel E5 Premium)

(09) Macrogol 6000

(10) titanium dioxide

(11) Talc

(12) iron oxide yellow 17015

(13) iron oxide red 17009

(14) Ethanol 96%

(15) water cleaned

II. PRODUCT DESCRIPTION

III. MANUFACTURING

A) Tablets 1 batch final mixture and tablets: 18000 g corresponds to 200000 tablets

1. Granulating fluid Purify water in a suitable mixing vessel (15) and add 664.092 g (14) ethanol 96% PAR INT 993.422 g (room temperature). Add successively (04) hydroxypropylcellulose (Klucel EF Pharm) INT 180,000 g and (01) formula (IA) citrate 39,600 g and dissolve. Solids content: 219.600 g 1877.114 g

Process data: Stirrer: SPN stirrer Speed / duration: approx. 250 - 450 rpm

2. Granules hi a suitable one-pot granulator

(02) Lactose fine INT 6085.400 g

(03) Lactose monohydrate (tablettose) Introduce INT 5800,000 g, mix homogeneously and mix with granulating liquid 1. Dampen 1877.114 g of solids: 219.600 g, granulate and then dry. 12105,000 g

Process data: Intensive mixer: Zanchetta Roto P 50

Nozzle head: 1.1 mm Spray pressure: approx. 2 bar Swivel angle: 100 ° (for drying and cooling)

During drying and cooling, the mixer should run continuously, 5 rpm.

3. Dry sieving Using a suitable sieving machine, shred the dried granules.

Process data: Screening machine: Comil 197 S Screen size: RS 2007 Spacer ring: DR 125

4. 'Final Mix In a suitable tumble mixer, dry sieve 3. 12105.000 g with (05) cellulose microcryst. Type 101 INT 5400,000 g (07) Carboxymethylcell-NA, cross-linked (Ac-Di-Sol) Mix INT 360,000 g. Subsequently add (06) magnesium stearate plant INT 135,000 g pre-screened over 0.5 mm and mix homogeneously. 18,000,000 g

Process data: Free-fall mixer: Servolift Kubus 60 1 Mis speed: 10 rpm Number of revolutions: 100 U (Ac-Di-Sol INT, MCC type 101) 30 U (MgSt.INT)

Tablets On a suitable tablet press the final mix 4. Press 18000,000 g into tablets. Target weight: 90 mg

Process data: Tablet press: Greases P1200 Tool: 6 mm WR 9, big arched with facet + BI logo Press speed 150,000 tbl / h Press force: approx. 7-9 kN

B) film-coated tablets

1 batch 2640 g = 29333 tablets 2713 g = 29333 film-coated tablets

6. coating suspension / solution (15) water purified 384.163 g (08) HypromeUose (Methocel E5 Prem) INT 36.666 g (07) Macrogol 6000 INT 3,667 g Stir in a suitable container (15), stir at room temperature (08) and (07) and dissolve (within 15 minutes). Solids content 40.333 g 424.496 g

7. coating suspension / dispersion

(15) water purified 164.623 g

(10) titanium dioxide TNT 18.304 g

(11) Talc INT 11,000 g

(12) iron oxide yellow 17015 INT 1.848 g

(13) Red iron oxide 17009 INT 1.848 g Place in a suitable container (15), suspend at room temperature (10), (11), (12) and (13) using an Ultra-Tunax and stir for 30 minutes. Solids content 33,000 g 197,623 g

8_ coating suspension coating suspension / solution 6. 424.496 g coating suspension / dispersion 7. 197.623 g Stir the dispersion 7. into the solution 6. and then stir for 5 minutes. Solids content 73.333 g 622.119 g

Filming In a suitable film coating device, tablet cores 5. 2639.970 g Coating suspension 8. 622.119 g Cover to a weight of 92.5 mg. Solids content 73.333 g 2713.303 g

Example 4 Examination of dissolution rate

The tablets according to Examples 1 and 2 are each dissolved in 900 ml of a simulated gastric fluid of pH 1.2 or a simulated intestinal flora of pH 6.8 (0.05 M phosphate buffer) at a stirring speed of 50 rpm or 75 rpm. The content of the dissolved compound of the formula (IA) is determined by HPLC.

The time course of this resolution can be seen in Figures 1 and 2. Where:

- ■ - Example 1 with wet-mix binder - ♦ - Example 2 without wet-mix binder

Claims

A solid pharmaceutical preparation containing one or more solid carriers and / or excipients and an active ingredient selected from the group consisting of monoamine neurotransmitter re-uptake inhibitors which have a 2,3-disubstituted tropane skeleton, obtainable by spraying a solution of this active ingredient on at least one carrier. 2. Solid pharmaceutical preparation containing one or more solid carriers and / or excipients and an active ingredient from the group of monoamine neurotransmitter re-uptake inhibitors, which have a 2,3-disubstituted tropane skeleton, characterized in that it contains at least one wet binder , 3. Pharmaceutical preparation according to claim 1 or 2, characterized in that the active ingredient is a compound of formula I. or their pharmaceutically acceptable acid addition salts or their N-oxides, wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or 2-hydroxyethyl; R ^{3 is} CH ₂ -XR ', where X is O, S, or NR ", where R" is hydrogen or alkyl; and R 'is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl or -CO-alkyl; Heteroaryl which may be monosubstituted or polysubstituted by alkyl, cycloalkyl or cycloalkylalkyl; Phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; phenylphenyl; Pyridyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; Thienyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or benzyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or (CH ₂ ) _n CO ₂ ^u , COR ¹¹ , or CH ₂ R ¹² , wherein R ^{π is} alkyl, cycloalkyl, or cycloalkylalkyl; Phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; phenylphenyl; Pyridyl which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or thienyl which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or benzyl; nist O or l; and is O-phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or O-CO-phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl; or CH = NOR '; wherein R 'is hydrogen; Alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl or aryl; which in turn is replaced by -COOH; -COO-alkyl; -COO-cycloalkyl may be substituted; or phenyl, which may be substituted one or more times by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, and nitro; R ⁴ is phenyl, 3,4-methylenedioxyphenyl, benzyl, naphthyl, or heteroaryl which is mono- or polysubstituted by a substituent selected from the group consisting of halogen, CF ₃ , CN, alkoxy, alkyl, alkenyl, alkynyl, amino, nitro, and heteroaryl may be substituted. 4. Pharmaceutical preparation according to one of the preceding claims, characterized in that the active substance is a compound of the formula II: wherein R ^{1 represents} a hydrogen atom or a C _1-6 alkyl group; R ^{2 is} a halogen atom or a is CF ₃ or cyano group; R ^{3 represents} a hydrogen atom or a C _1-6 alkyl group or C _3-6 cycloalkyl C _1-3 alkyl group; and m is 0 or an integer from 1 to 3; or a tautomer, a pharmaceutically acceptable salt, solvate, or a physiological functional derivative thereof. 5. Pharmaceutical preparation according to one of the preceding claims, characterized in that the active ingredient is a compound of the formula IA or a pharmaceutically acceptable salt thereof. 6. Pharmaceutical preparation according to one of the preceding claims obtainable by spraying a solution of the active ingredient, wherein the solvent contains water, an alcohol and optionally a wet binder. 7. Pharmaceutical preparation according to one of the preceding claims, characterized in that the wet binder is hydroxypropyl cellulose (HPC). 8. Pharmaceutical preparation form according to one of the preceding claims, characterized in that the active ingredient during spraying in predominantly crystalline form on the carrier material precipitated. 9. Pharmaceutical preparation according to one of the preceding claims, characterized in that the carrier materials are selected from the group consisting of carbohydrates and dry binders. 10. Pharmaceutical preparation form according to one of the preceding claims, characterized in that the carrier materials consist essentially of lactose and cellulose. 11. Pharmaceutical preparation according to one of the preceding claims, characterized in that the carrier materials consist essentially of anhydrous lactose, lactose monohydrate and microcrystalline cellulose. 12. A pharmaceutical formulation according to any one of the preceding claims, characterized in that the excipients are selected from the group consisting of wet binders, lubricants, disintegrants, release agents and wetting agents. 13. Pharmaceutical preparation according to one of the preceding claims, characterized in that the auxiliaries consist essentially of cellulose derivatives and salts of fatty acids. 14. A pharmaceutical formulation according to any one of the preceding claims, characterized in that the auxiliaries consist essentially of hydroxypropyl cellulose (HPC), carboxymethyl cellulose Na, cross-linked (croscarmellose) and magnesium stearate. A pharmaceutical preparation according to any one of the preceding claims, characterized in that it is a film-coated tablet. 16. Pharmaceutical preparation according to claim 14, characterized in that the film coating consists essentially of one or more film formers, one or more elasticity-increasing agents, one or more release agents, one or more pigments and optionally one or more dyes. 17. A pharmaceutical formulation according to claim 14 or 15, characterized in that the film coating hydroxypropylmethylcellulose (HPMC), methylhydroxypropylcellulose (MHPC), polyethylene glycol (PEG), one or more silicates, titanium dioxide, and one or more iron oxides. 18. Pharmaceutical preparation according to one of the preceding claims, characterized in that it consists essentially of the following components: (i) a drug from the group of monoamine neurotransmitter re-uptake inhibitors which have a 2,3-disubstituted tropane backbone; (ii) one or more carrier materials selected from the group consisting of carbohydrates and dry binders; (iii) one or more adjuvants selected from the group consisting of cellulose derivatives and salts of fatty acids; (iv) a film coating consisting essentially of one or more film formers, one or more elasticity enhancing agents, one or more pigments and optionally one or more colorants. 19. A pharmaceutical formulation according to any one of the preceding claims, characterized in that it consists essentially of the following components: (i) 0.01 to 5.00 wt .-%> of an active ingredient from the group of monoamine neurotransmitter re-uptake inhibitors, which have a 2,3-disubstituted tropane skeleton; (ii) from 80.00% to 95.00% by weight of one or more carrier materials selected from the group consisting of carbohydrates and dry binders; (iii) 1.00 to 10.00% by weight of one or more adjuvants selected from the group consisting of cellulose derivatives and salts of fatty acids; (Iv) 0 to 10.00 wt .-% of a film coating consisting essentially of one or more film formers, one or more elasticity-increasing agents, one or more pigments and optionally one or more dyes. 20. Pharmaceutical preparation according to one of the preceding claims, characterized in that it consists essentially of the following components: (i) 0.02 to 3.00 wt .-% of an active ingredient of the formula I; (ii) a carrier material consisting of: d. 27.5 to 32.5% by weight of anhydrous lactose; e. 27.5 to 32.5% by weight of lactose monohydrate; f. 25.0 to 30.0% by weight of microcrystalline cellulose; (iii) from 2.00% to 8.00% by weight of one or more adjuvants selected from the group consisting of HPC, CMC and magnesium stearate; (iv) 1.00 to 5.00 of a film coating comprising HPMC, PEG, one or more silicates, titanium dioxide and one or more iron oxides. 21. A process for the preparation of a pharmaceutical preparation according to one of claims 1 to 20, characterized in that one (A) an active ingredient selected from the group of monoamine neurotransmitter re-uptake inhibitors, which has a 2,3-disubstituted tropane skeleton, in a suitable solvent, optionally in the presence of an excipient dissolves; (b) spraying the resulting solution onto one or more solid carriers; (c) optionally adding further excipients and auxiliaries; (d) shaping and optionally pressing the resulting mixture; and (e) optionally applying a suitable film coating. 22. Use of a pharmaceutical preparation according to any one of claims 1 to 20 for the manufacture of a medicament for the treatment or prevention of central nervous disorders or disorders selected from the group consisting of depression, any form of dementia, Parkinson's disease or obesity.